MAPK-driven glioma progression and reprogramming of the tumor-associated immune response

Clicks: 2
ID: 319323
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #124 of 219 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 219 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: In brain tumors, the immunosuppressive microenvironment leads to tumor aggressiveness and immunotherapy resistance. To identify factors that regulate the glioma immune landscape, we took advantage of the disease trajectory of the MAPK-driven glioma, pleomorphic xanthoastrocytoma (PXA), which evolves from an immune-rich low-grade tumor to an aggressive glioma. METHODS: Using a multiomics approach that included single-nucleus RNA sequencing (snRNA-seq), spatial transcriptomics, and spatial proteomics, a cohort of 38 tumors, including 10 longitudinal pairs, was profiled. RESULTS: Tumor progression was associated with transition to a more proliferative progenitor state and increased hypoxia. Hypoxic reprogramming of the immune landscape included increased TGF-β signaling and altered chemokine signaling, including decreased CXCL14 and CXCL16-CXCR6 signaling important in immune cell recruitment and activation. The resulting immune landscape was spatially reorganized with reduced HLA Class II expression, reduced CD8+ and CD4⁺ T cells, and dominated by immunosuppressive myeloid cells. CONCLUSIONS: Hypoxia and chemokine signaling emerged as key components of the glioma-immune landscape that evolve with tumor progression. These findings identify potential therapeutic opportunities in PXA, and they argue that optimal immunomodulatory strategies in glioma will differ along the disease trajectory.
Reference Key
openalex_W7166673393 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elaheh Hashemi, R.L. Akshaya, Lin Wang, Spencer Bergland, Hadeesha Piyadasa, Jolene S Ranek, Viva Voong, Aditya Kshirsagar, Anny Shai, Benjamin Oberlton, Anupam Kumar, Mitchel S Berger, Edward F. Chang, Michael C. Oldham, Robert M. Prins, Sean C. Bendall, Michael Angelo, Shawn L Hervey-Jumper, Hideho Okada, Aaron Diaz, Joanna J Phillips
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag147
URL
https://doi.org/10.1093/neuonc/noag147
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.